June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.
April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.
Communities Should Be Involved in Research. Here Are Some Key Insights on Good Participatory Practice.
Increasingly, researchers are looking for ways to involve communities not just by participating in trials, but by helping shape these projects. But, how do you go about making sure affected communities are at the table?
Primary care providers need more education when it comes to PrEP, not only for them, but also for patients, who often think they need to see a specialist just to take this preventative medicine.
A fascinating lecture at this year's HIVR4P conference showed how advances in modern scanning technologies can be used to get more accurate information about the first stages of HIV infection and on the ways that HIV drugs are absorbed and distribute...
Gauging treatment priority when CD4 count is high; the effect of hepatitis C coinfection on response to HIV treatment; HIV, aging and comorbidity in Africa; PrEP and drug-resistant gonorrhea.
For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes.
During the early stages of infection, HIV mounts a severe and prolonged attack on the gut, which harbors a rich population of CD4 T cells. Watch a two-minute animation describing the process.
One study in Amsterdam deployed a strategy to identify acute HIV in men who have sex with men (MSM) and then link newly diagnosed individuals to care.
Number of viral load blips during antiretroviral therapy begun during acute HIV infection predicted viral rebound when treatment stopped in a 228-person international study.